GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Regenerative Medicine International Ltd (HKSE:08158) » Definitions » Asset Turnover

China Regenerative Medicine International (HKSE:08158) Asset Turnover : 0.00 (As of Jun. 2024)


View and export this data going back to 2001. Start your Free Trial

What is China Regenerative Medicine International Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. China Regenerative Medicine International's Revenue for the three months ended in Jun. 2024 was HK$0.00 Mil. China Regenerative Medicine International's Total Assets for the quarter that ended in Jun. 2024 was HK$165.49 Mil. Therefore, China Regenerative Medicine International's Asset Turnover for the quarter that ended in Jun. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. China Regenerative Medicine International's annualized ROE % for the quarter that ended in Jun. 2024 was 0.00%. It is also linked to ROA % through Du Pont Formula. China Regenerative Medicine International's annualized ROA % for the quarter that ended in Jun. 2024 was 0.00%.


China Regenerative Medicine International Asset Turnover Historical Data

The historical data trend for China Regenerative Medicine International's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Regenerative Medicine International Asset Turnover Chart

China Regenerative Medicine International Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.52 1.38 0.16 0.30

China Regenerative Medicine International Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.16 0.04 -0.23 -

Competitive Comparison of China Regenerative Medicine International's Asset Turnover

For the Biotechnology subindustry, China Regenerative Medicine International's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Regenerative Medicine International's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Regenerative Medicine International's Asset Turnover distribution charts can be found below:

* The bar in red indicates where China Regenerative Medicine International's Asset Turnover falls into.


;
;

China Regenerative Medicine International Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

China Regenerative Medicine International's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=69.487/( (275.911+185.897)/ 2 )
=69.487/230.904
=0.30

China Regenerative Medicine International's Asset Turnover for the quarter that ended in Jun. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=0/( (185.897+145.074)/ 2 )
=0/165.4855
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


China Regenerative Medicine International  (HKSE:08158) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

China Regenerative Medicine International's annulized ROE % for the quarter that ended in Jun. 2024 is

ROE %**(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=0/18.464
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0 / 0)*(0 / 165.4855)*(165.4855/ 18.464)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*8.9626
=ROA %*Equity Multiplier
=0.00 %*8.9626
=0.00 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

China Regenerative Medicine International's annulized ROA % for the quarter that ended in Jun. 2024 is

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=0/165.4855
=(Net Income / Revenue)*(Revenue / Total Assets)
=(0 / 0)*(0 / 165.4855)
=Net Margin %*Asset Turnover
= %*0
=0.00 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


China Regenerative Medicine International Asset Turnover Related Terms

Thank you for viewing the detailed overview of China Regenerative Medicine International's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


China Regenerative Medicine International Business Description

Traded in Other Exchanges
N/A
Address
132 Nathan Road, Suite 2310-18, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG
China Regenerative Medicine International Ltd is an investment holding company engaged in the provision of healthcare products and services. Its reportable segments are Aesthetic medical and beauty services and Medical services. The vast majority of the company's revenue is derived from its Aesthetic medical and beauty services segment. Geographically, the People's Republic of China accounts for the majority of the revenue. It also has a presence in Hong Kong.
Executives
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Wang Chuang 2101 Beneficial owner
Arab Osman Mohammed 2501 Other
Wong Kwok Keung 2501 Other
Lei Changjuan 2101 Beneficial owner
Chang Zhou Shi Zhong Min Xing Kong Qi Ye Guan Li Zi Xun Fu Wu He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Kong Yudong 2101 Beneficial owner
Chang Zhou Shi Yao Guang Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Li Ren 2201 Interest of corporation controlled by you
Nat-ace Wood Industry Ltd. (formerly Known As Forerunner Technology Limited) 2201 Interest of corporation controlled by you
All Favour Holdings Limited 2101 Beneficial owner
Deng Shufen 2202 Interest of your spouse
Dai Yumin 2201 Interest of corporation controlled by you
Wang Xiaogang 2101 Beneficial owner
China Orient Asset Management Co., Ltd. 2106 Person having a security interest in shares

China Regenerative Medicine International Headlines

No Headlines